我们为何应关注超罕见疾病。
Why we should care about ultra-rare disease.
作者信息
Harari Sergio
机构信息
U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria-Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe-MultiMedica IRCCS, Milan, Italy
出版信息
Eur Respir Rev. 2016 Jun;25(140):101-3. doi: 10.1183/16000617.0017-2016.
Abstract
摘要
这看起来并不是一段可翻译的文本内容，它是一个网址链接：http://ow.ly/Zlmf4 。
相似文献
1
Why we should care about ultra-rare disease.
Eur Respir Rev. 2016 Jun;25(140):101-3. doi: 10.1183/16000617.0017-2016.
2
Global effort against rare and orphan diseases.
Eur Respir Rev. 2012 Sep 1;21(125):171-2. doi: 10.1183/09059180.00004112.
3
Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe.
Respir Med. 2012 Jun;106(6):759-68. doi: 10.1016/j.rmed.2012.02.016. Epub 2012 Mar 11.
4
Adopting an orphan.
EMBO Rep. 2005 Jun;6(6):507-10. doi: 10.1038/sj.embor.7400450.
5
Rare lung disease and orphan drug development.
Lancet Respir Med. 2013 Aug;1(6):479-87. doi: 10.1016/S2213-2600(13)70085-7. Epub 2013 Jun 25.
6
Confusion over Article 8.
EMBO Rep. 2005 Aug;6(8):690. doi: 10.1038/sj.embor.7400485.
7
Policy alternatives for treatments for rare diseases.
CMAJ. 2010 Nov 23;182(17):E787-92. doi: 10.1503/cmaj.081429. Epub 2010 Jul 12.
8
We need a "made in Canada" orphan drug framework.
CMAJ. 2017 Oct 16;189(41):E1274-E1275. doi: 10.1503/cmaj.170195.
9
Orphanage at the FDA.
J Cardiovasc Transl Res. 2012 Oct;5(5):735-6. doi: 10.1007/s12265-010-9242-2. Epub 2010 Nov 16.
10
Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
Eur Respir Rev. 2015 Sep;24(137):375-7. doi: 10.1183/16000617.0051-2015.
引用本文的文献
1
Case Report: A neurodevelopmental disorder with global developmental delay, microcephaly, eye anomalies, sweat dysregulation, and skeletal implications due to an ultra-rare 5q14.3q15 copy number gain.
Front Genet. 2025 May 26;16:1549685. doi: 10.3389/fgene.2025.1549685. eCollection 2025.
2
Novel pathogenic ATM mutation with ataxia-telangiectasia in a Chinese family.
Front Genet. 2024 Nov 28;15:1491649. doi: 10.3389/fgene.2024.1491649. eCollection 2024.
3
"In God We Trust": An Exploratory Study of the Associations Between Religiosity and the Caregiving Experiences of Parents of Children with Rare Diseases in Poland.
J Relig Health. 2024 Dec;63(6):4079-4109. doi: 10.1007/s10943-024-02095-4. Epub 2024 Aug 5.
4
Clinical description and evaluation of 30 pediatric patients with ultra-rare diseases: A multicenter study with real-world data from Saudi Arabia.
PLoS One. 2024 Jul 18;19(7):e0307454. doi: 10.1371/journal.pone.0307454. eCollection 2024.
5
Meeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs.
Open Forum Infect Dis. 2024 Jun 17;11(6):ofae257. doi: 10.1093/ofid/ofae257. eCollection 2024 Jun.
6
Literature Review on Health Emigration in Rare Diseases-A Machine Learning Perspective.
Int J Environ Res Public Health. 2023 Jan 30;20(3):2483. doi: 10.3390/ijerph20032483.
7
Rare disease emerging as a global public health priority.
Front Public Health. 2022 Oct 18;10:1028545. doi: 10.3389/fpubh.2022.1028545. eCollection 2022.
8
Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa.
Orphanet J Rare Dis. 2022 Sep 29;17(1):367. doi: 10.1186/s13023-022-02509-0.
9
Treating rare diseases with the cinema: Can popular movies enhance public understanding of rare diseases?
Orphanet J Rare Dis. 2022 Mar 5;17(1):117. doi: 10.1186/s13023-022-02269-x.
10
DDA-SKF: Predicting Drug-Disease Associations Using Similarity Kernel Fusion.
Front Pharmacol. 2022 Jan 13;12:784171. doi: 10.3389/fphar.2021.784171. eCollection 2021.
本文引用的文献
1
Thoracic involvement in generalised lymphatic anomaly (or lymphangiomatosis).
Eur Respir Rev. 2016 Jun;25(140):170-7. doi: 10.1183/16000617.0018-2016.
2
Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide.
Eur Respir Rev. 2015 Dec;24(138):607-20. doi: 10.1183/16000617.0036-2015.
3
ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia.
Eur Respir Rev. 2015 Dec;24(138):565-81. doi: 10.1183/16000617.0066-2015.
4
Multiple cystic lung disease.
Eur Respir Rev. 2015 Dec;24(138):552-64. doi: 10.1183/16000617.0046-2015.
5
High quality, patient centred and coordinated care for Alstrom syndrome: a model of care for an ultra-rare disease.
Orphanet J Rare Dis. 2015 Nov 24;10:149. doi: 10.1186/s13023-015-0366-y.
6
The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.
Orphanet J Rare Dis. 2015 Jul 30;10:92. doi: 10.1186/s13023-015-0305-y.
7
Rare (pulmonary) disease day: "feeding the breath, energy for life!".
Eur Respir J. 2015 Feb;45(2):297-300. doi: 10.1183/09031936.00221914.
8
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders.
J Comp Eff Res. 2014 Jul;3(4):399-422. doi: 10.2217/cer.14.34.
9
Care for patients with ultra-rare disorders.
Eur J Med Genet. 2011 May-Jun;54(3):220-4. doi: 10.1016/j.ejmg.2010.12.001. Epub 2010 Dec 10.
10
Orphan drug development is not taking off.
Br J Clin Pharmacol. 2009 May;67(5):494-502. doi: 10.1111/j.1365-2125.2009.03369.x. Epub 2009 Jan 21.
Zotero 插件